Post anti-PD-1 therapy, the myeloid-infiltrating cells exhibited elevated expression of checkpoint ligands, particularly notable for LAG3 ligands, and molecules such as TREM2, CSF1R, and IL1B, a monocyte cytokine previously associated with resistance in MMRd CRC tumors 17. The gene discussed is PDCD1; the disease is colorectal carcinoma.